List of Sumavel Dosepro drug patents

Sumavel Dosepro is owned by Endo Ventures Ltd.

Sumavel Dosepro contains Sumatriptan Succinate.

Sumavel Dosepro has a total of 9 drug patents out of which 3 drug patents have expired.

Expired drug patents of Sumavel Dosepro are:

  • US8343130
  • US8491524
  • US8241244

Sumavel Dosepro was authorised for market use on 15 July, 2009.

Sumavel Dosepro is available in injectable;subcutaneous dosage forms.

The generics of Sumavel Dosepro are possible to be released after 22 November, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8343130 ENDO VENTURES LTD Needleless injector
Oct, 2022

(3 months ago)

US8491524 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(2 months ago)

US8241244 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(2 months ago)

US8267903 ENDO VENTURES LTD Casing
Mar, 2023

(a month from now)

US8241243 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Aug, 2023

(6 months from now)

US8118771 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Aug, 2023

(6 months from now)

US8287489 ENDO VENTURES LTD Device for readying a needle free injector for delivery
Dec, 2024

(1 year, 9 months from now)

US7901385 ENDO VENTURES LTD Casing
Jul, 2026

(3 years from now)

US7776007 ENDO VENTURES LTD Device for readying a needle free injector for delivery
Nov, 2026

(3 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 July, 2009

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic